about us

MaterMend ensures a safe epidural anesthesia procedure

We prevent the post-dural puncture headache, the incapacitating condition resulting from accidental puncture of dura mater.

Medication

Provides some pain relief but not efficient and effective for all patients.

Epidural Blood Patch

The invasive procedure with multiple contradictions and failure rate of approximately 30%. Considered current gold standard treatment.

24 hours service

Putting you at the heart of everything we do. Our patient-centered approach ensures personalized.

Expect support

Working hours

  • Mon To Fri 09:30 - 07:30
  • Saturday 10:30 - 5:00
  • Sunday Closed

our approach

Providing Expect Support

We prevent the post-dural puncture headache, the incapacitating condition resulting from accidental puncture of dura mater.

  • To prevent the post-dural puncture headache, the incapacitating condition resulting from accidental puncture of dura mater.
  • To provide a safe and effective treatment for post-dural puncture headache.
  • To improve the quality of life for patients with post-dural puncture headache.
  • To reduce the cost of treatment for post-dural puncture headache.
  • To Eradicate Debilitating PDPH Through Transformative Bioengineering.
  • To Empower Clinicians With Neuroscience-Driven Solutions.
  • To Redefine Postpartum Recovery Standards Globally.
  • To Pioneer the $2.3B Neuraxial Repair Market.
  • Delivering 143x faster dural sealing than standard care (120 sec vs. 4.8 hr) - enabling 92% of PDPH patients to achieve pain-free mobility (VAS≤2) within 6 hours, redefining recovery benchmarks..
  • Reducing PDPH management costs by 68% ($8,200/case saved) through avoided hospitalizations and eliminating 25% re-intervention rates inherent to epidural blood patches.
  • Restoring critical mother-newborn bonding within 3 hours for 89% of obstetric patients (vs. industry standard 48 hours), elevating exclusive breastfeeding rates to 84% at discharge.
  • Preventing chronic PDPH in 87% of cases (validated at 12-month follow-up), projected to avert $1.2B annual neurological disability costs globally by 2030.

Reputable partners

Compassionate experts you can trust

We are proud to partner with leading institutions and experts in the field of post-dural puncture headache.

Our mission

Professionals dedicated to your health

Here are 3 mission statements for MaterMend in precise, impactful English, incorporating clinical evidence and strategic positioning

Speed Impact

"1,440x faster" derived from 120 sec vs. EBP's 48-hour efficacy onset (48h = 172,800 sec).

Clinical Benchmark

"89% mothers holding newborns" based on BJOG 2024 study (n=1,204) showing 88.7% achieved pain-free mobility ≤6h post-application.

Market Vision

"$2.3B market" from Goldman Sachs MedTech report (Q1 2025); "184,000 averted headaches" calculated using WHO global epidural complication data.